Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.
Oncol Rep. 2018 Feb 09;:
Authors: Li C, Yang C, Wei G
Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.